Deutsche Bank AG Acquires New Stake in Boston Scientific Corporation $BSX

Deutsche Bank AG acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 5,957,053 shares of the medical equipment provider’s stock, valued at approximately $254,247,000.

A number of other large investors have also bought and sold shares of BSX. Vanguard Group Inc. lifted its position in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after buying an additional 1,436,550 shares during the last quarter. State Street Corp increased its holdings in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares during the last quarter. Capital World Investors raised its stake in Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after acquiring an additional 502,627 shares during the period. Norges Bank purchased a new stake in Boston Scientific during the fourth quarter valued at about $2,199,395,000. Finally, Morgan Stanley lifted its holdings in Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BSX shares. Weiss Ratings lowered shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. BTIG Research dropped their target price on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. Robert W. Baird set a $56.00 price target on Boston Scientific in a report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research report on Thursday, May 28th. Finally, Bank of America dropped their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Stock Performance

Shares of BSX opened at $50.51 on Wednesday. The company has a market cap of $73.20 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average price of $46.15 and a 200-day moving average price of $58.50. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 194,522 shares of company stock valued at $9,385,210 in the last quarter. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.